

Accepted Manuscript

Title: Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus

Authors: Maurílio de Souza Cazarim, Estael Luzia Coelho da Cruz-Cazarim, André de Oliveira Baldoni, Thais Bueno Enes dos Santos, Paula Gonçalves de Souza, Ingrid de Almeida Silva, Roberta Niriam Reis Rodrigues, Alda Cristina Franco Correa Maia, Leonardo Régis Leira Pereira, Cristina Sanches-Giraud



PII: S1871-4021(17)30179-0
DOI: <http://dx.doi.org/doi:10.1016/j.dsx.2017.07.006>
Reference: DSX 808

To appear in: *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*

Received date: 31-5-2017
Accepted date: 1-7-2017

Please cite this article as: Cazarim Maurílio de Souza, da Cruz-Cazarim Estael Luzia Coelho, de Oliveira Baldoni André, dos Santos Thais Bueno Enes, de Souza Paula Gonçalves, Silva Ingrid de Almeida, Rodrigues Roberta Niriam Reis, Maia Alda Cristina Franco Correa, Pereira Leonardo Régis Leira, Sanches-Giraud Cristina. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* <http://dx.doi.org/10.1016/j.dsx.2017.07.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus

Maurílio de Souza Cazarim¹; Estael Luzia Coelho da Cruz-Cazarim²; André de Oliveira Baldoni³; Thais Bueno Enes dos Santos⁴; Paula Gonçalves de Souza⁵; Ingrid de Almeida Silva⁶; Roberta Niriam Reis Rodrigues⁷; Alda Cristina Franco Correa Maia⁸; Leonardo Régis Leira Pereira⁹; Cristina Sanches-Giraud¹⁰

¹ Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil. (*Corresponding author*). Email: mscazarim@usp.br

² Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo. Email: estaelcruz@fcfrp.usp.br

³ Federal University of São João Del-Rei (UFSJ). Email: andrealdoni@ufs.edu.br

⁴ Federal University of São João Del-Rei (UFSJ). Email: enesthais@gmail.com

⁵ Federal University of São João Del-Rei (UFSJ). Email: paula.gsouza@hotmail.com

⁶ Federal University of São João Del-Rei (UFSJ). Email: ingrid-almeida@hotmail.com

⁷ Federal University of São João Del-Rei (UFSJ). Email: robertaniriam@gmail.com

⁸ Federal University of São João Del-Rei (UFSJ). Email: aldinhamaiia@hotmail.com

⁹ Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo. Email: lpereira@fcfrp.usp.br

¹⁰ Federal University of São João Del-Rei (UFSJ). Email: csgiraud@ufs.edu.br

HIGHLIGHTS:

- It was performed the sensitivity analysis of cost effectiveness ratio was conducted by the decision tree, which was built on the thresholds of the effectiveness of each drug. This makes it possible to check which drug is most likely to be cost effective, given the change in HbA1c achieved by it.

Download English Version:

<https://daneshyari.com/en/article/8658929>

Download Persian Version:

<https://daneshyari.com/article/8658929>

[Daneshyari.com](https://daneshyari.com)